medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2016, Número 3

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2016; 14 (3)


Psoriasis ungueal: opciones terapéuticas

Gallegos RMA, Villanueva QDG, Barba GJF

Idioma: Español
Referencias bibliográficas: 50
Paginas: 237-244
Archivo PDF: 149.90 Kb.


RESUMEN

La psoriasis es una enfermedad autoinflamatoria mediada por citocinas, crónica y al día de hoy, incurable. Puede involucrar piel, articulaciones y uñas. La afectación ungueal se presenta en más del 50% de los pacientes y puede condicionar un impacto significativo en su calidad de vida. Constituye por sí misma un notable reto terapéutico. Los fármacos biológicos son los agentes de mayor eficacia. Se presenta una revisión con respecto a las opciones de tratamiento existentes en psoriasis ungueal.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. van de Kerkhof PCM, Nestle FO. Psoriasis. En: Bolognia JL, Jorizzo JL, Schaffer JV, editores. Dermatology. 3a ed. China: Elsevier 2012; 135-156.

  2. Rosso KR, Murussi N, Neumaier W et al. Nail psoriasis: a review of the literature. An Bras Dermatol 2014; 89(2): 312-7.

  3. Gudjonsson JE, Elder JT. Psoriasis. En: Goldsmith LA, Katz SI, Paller AS, editores. Fitzpatrick Dermatología en Medicina General. 8a ed. Madrid: Panamericana 2014; 197-232.

  4. Sánchez-Regaña M, Umbert-Millet P. Aspectos diagnósticos y terapéuticos de la psoriasis ungueal. Actas Dermosifiliogr 2008; 99(1): 34-43.

  5. Tan ES, Chong WS, Tey HL. Nail Psoriasis: A Review. Am J Clin Dermatol 2012; 13(6): 375-88.

  6. de Vries ACQ, Bogaards NA, Hooft L et al. Interventions for nail psoriasis. Cochrane Database of Systematic Reviews 2013, Issue 1; Art. No.: CD007633. DOI: 10.1002/14651858.CD007633.pub2.

  7. Langley RG, Saurat JH, Reich K. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. J Eur Acad Dermatol Venereol 2012; 26(3): 373-81.

  8. Pasch MC. Nail Psoriasis: A Review of Treatment Options. Drugs 2016; 76(6): 675-705.

  9. Langenbruch A, Radtke MA, Krensel M et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol 2014; 171(5): 1123-8.

  10. Oram Y, Akkaya D. Treatment of Nail Psoriasis: Common Concepts and New Trends. Dermatol Res Pract 2013; 2013(5): 180496. doi: 10.1155/2013/180496.

  11. Tosti A, Piraccini BM. Biología de las uñas y trastornos ungueales. En: Goldsmith LA, Katz SI, Paller AS, editores. Fitzpatrick Dermatología en Medicina General. 8a ed. Madrid: Panamericana 2014; 1009-30.

  12. Wiznia LE, Quatrano NA, Mu EW, Rieder EA. A Clinical Review of Laser and Light Therapy for Nail Psoriasis and Onychomycosis. Dermatol Surg 2016; [Epub ahead of print]

  13. Radtke MA, Langenbruch AK, Schäfer I et al. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas 2011; 2: 1-6.

  14. de Jong EM, Seegers BA, Gulinck MK et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996; 193(4): 300-3.

  15. Baran R. The burden of nail psoriasis: an introduction. Dermatology 2010; 221: 1-5.

  16. Baran R, Tosti A. Topical treatment of nail psoriasis with a new corticoid- containing nail lacquer formulation. J Dermatol Treat 1999; 10(3): 201-4.

  17. Nakamura RC, Abreu LD, Duque-Estrada B et al. Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treat- ment: prospective, controlled and randomized pilot study. An Bras Dermatol 2012; 87(2): 203-11.

  18. Sánchez-Regaña M, Ojeda-Cuchillero R, Umbert-Millet P. Empleo de calcipotriol tópico en la psoriasis ungueal. Piel 2002; 17(3): 104-8.

  19. Tosti A, Piraccini BM, Cameli N et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998; 139(4): 655-9.

  20. Márquez-Balbás G, Sánchez-Regaña M, Umbert-Millet P. Tacalcitol ointment for the treatment of nail psoriasis. J Dermatolog Treat 2009; 20(5): 308-10.

  21. Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05 % cream: a double-blind study. Acta Derm Venereol 2007; 87(2): 167-8.

  22. Fischer C, Sanchez M, Llambi F et al. Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment. Actas Dermosifiliogr 2012; 103(8): 725-8.

  23. Cannavo SP, Guarneri F, Vaccaro M et al. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology 2003; 206(2): 153-6.

  24. De Simone C, Maiorino A, Tassone F et al. Tacrolimus 0.1 % ointment in nail psoriasis: a randomized controlled open-label study. J Eur Acad Dermatol Venereol 2013; 27(8): 1003-6.

  25. Fritz K. Successful local treatment of nail psoriasis with 5-fluorouracil. Z Hautkr 1989; 64(12): 1083-8.

  26. Maranda EL, Nguyen AH, Lim VM et al. Laser and light therapies for the treatment of nail psoriasis. J Eur Acad Dermatol Venereol 2016; 30(8): 1278-84.

  27. Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol 1998; 25(4): 231–3.

  28. 28.- Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernández M, Umbert-Millet P. “Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy)”. J Eur Acad Dermatol Venereol 2011; 25(5): 579–586.

  29. 29.- Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini BM. “Evaluation of the efficacy of acitretin therapy for nail psoriasis”. Arch Dermatol 2009; 145(3): 269–271.

  30. Mukai MM, Poffo IF, Werner B et al. NAPSI utilization as an evaluation method of nail psoriasis in patients using acitretin. An Bras Dermatol 2012; 87(2): 256-62.

  31. Gumusel M, Ozdemir M, Mevlitoglu I, Bodur S. Evaluation of the effi- cacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 2011; 25(9): 1080-4.

  32. Lee JY. Severe 20-nail psoriasis successfully treated by low dose methotrexate. Dermatol Online J 2009; 15(11): 8.

  33. Karanikolas GN, Koukli EM, Katsalira A et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol 2011; 38(11): 2466-74.

  34. Feliciani C, Zampetti A, Forleo P et al. Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg 2004; 8(2): 122-5.

  35. Rigopoulos D, Gregoriou S, Stratigos A et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol 2008; 159(2): 453-6.

  36. Rich P, Griffiths CE, Reich K et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58(2): 224-31.

  37. Ortonne JP, Paul C, Berardesca E et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol 2013; 168(5): 1080-7.

  38. Van den Bosch F, Manger B, Goupille P et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69: 394-9.

  39. Armesto S, Esteve A, Coto P et al. Nail psoriasis in individuals with psoriasis vulgaris: a study of 661 patients. Actas Dermosifiliogr 2011; 102(5): 365-72.

  40. Saraceno R, Pietroleonardo L, Mazzotta A et al. TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis. Expert Opin Biol Ther 2013; 13(4): 469-473.

  41. Kyriakou A, Patsatsi A, Sotiriadis D. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study. J Dermatolog Treat 2013; 24(3): 162-8.

  42. Leonardi C, Langley RG, Papp K et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 2011; 147(4): 429-36.

  43. Crowley JJ, Weinberg JM, Wu JJ et al. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol 2015; 151(1): 87-94.

  44. Saricaoglu H, Oz A, Turan H. Nail psoriasis successfully treated with intralesional methotrexate: case report. Dermatology 2011; 222(1): 5-7.

  45. Aubin F, Vigan M, Puzenat E et al. Evaluation of a novel 308-nm monochromatic excimer light delivery system in dermatology: a pilot study in different chronic localized dermatoses. Br J Dermatol 2005; 152(1): 99-103.

  46. Fernández-Guarino M, Harto A, Sánchez-Ronco M et al. Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study. J Eur Acad Dermatol Venereol 2009; 23(8): 891-5.

  47. Tawfik AA. Novel treatment of nail psoriasis using the intense pulsed light: a one-year follow-up study. Dermatol Surg 2014; 40(7): 763-8.

  48. Treewittayapoom C, Singvahanont P, Chanprapaph K, Haneke E. The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, doubleblind, intrapatient left-to-right study. J Am Acad Dermatol 2012; 66(5): 807-12.

  49. Oram Y, Karincaoglu Y, Koyuncu E, Kaharaman F. Pulsed dye laser in the treatment of nail psoriasis. Dermatol Surg 2010; 36(3): 377-81.

  50. Al-Mutairi N, Noor T, Al-Haddad A. Single Blinded Left-to-Right Comparison Study of Excimer Laser Versus Pulsed Dye Laser for the Treatment of Nail Psoriasis. Dermatol Ther (Heidelb) 2014; 4(2): 197-205.




2020     |     www.medigraphic.com